



## For Immediate Release

Contact: Bill Littlefield  
Respironics/Mini Mitter  
Product Manager  
541-598-3850

Sandy Binder  
Respironics, Inc.  
MarComm Planner  
724-387-4079

### **Introduction of New Smaller Running Wheel Specifically Designed with Smaller Rodents in Mind**

**Murrysville, PA, August 31, 2006 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP)** announces the release of new smaller wheels for the behavioral monitoring of mice and other small rodents in the animal research market. The new running wheels, available in sizes of 4-1/2 and 7 inches, are designed specifically to meet researchers' needs to use standard cages and racks and collect wheel turn data.

The smaller wheels are completely contained within the cage and can be filter-top compatible; they are designed to provide long-term durability and convenience. The entire line of wheels provides monitoring information on circadian rhythm and activity; this data can be combined with body temperature, activity and heart rate data from the E-Mitter transponders for a complete physiological and behavioral picture of research subjects.

According to Bill Littlefield, product manager, "These mouse wheels offer customers practicality and convenience as they are a lower cost wheel solution, take up less space, provide enrichment and supply reliable wheel turn data 24/7."

Mini Mitter develops and markets a range of physiological and behavioral monitoring products, including devices that measure sleep-wake activity, dermal and core body temperature, heart rate and energy expenditure. The Company markets these products to commercial sleep laboratories and other medical, pharmaceutical and health research institutions involved in clinical trials.

#### **CORPORATE SERVICES**

1010 Murry Ridge Lane • Murrysville, PA 15668  
Phone 724.387.5200 • Fax 724.387.5010



Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,800 associates worldwide. Further information can be found on the Company's Web site: [www.respironics.com](http://www.respironics.com).

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K. Respironics stated that it will not be changing its financial outlook or guidance based on this announcement.

© 2007 Respironics, Inc. and its affiliates

###